ARCHIVES

Letrozole Cuts Risk Of Breast Cancer Recurrence Even After Tamoxifen Use

This article is from The Cancer Letter archive.

Vol. 31 No. 3 | March 28, 2008

Download PDF Visit The Full Archive

Related Articles

Switching to Tasigna After Gleevec Therapy Can Achieve Deeper Molecular Response

December 28, 2012

Genetic Testing: No Easy Answers To Public Questions

May 15, 1998

Amgen Halts Phase III Trial Of Ganitumab Plus Gemcitabine

August 31, 2012

In Brief: appropriations Approved; Grants, contracts May Flow Unimpeded; NCI Positions An Issue

December 16, 1977

FDA Committee Okays Carboplatin For Second Line Ovarian Cancer

January 6, 1989

West Coast Symposium Reports Research Progress On Bone Cancer

November 1, 1974